1.86
price up icon0.54%   0.01
after-market Handel nachbörslich: 1.86
loading
Schlusskurs vom Vortag:
$1.85
Offen:
$1.85
24-Stunden-Volumen:
2.49M
Relative Volume:
1.46
Marktkapitalisierung:
$391.14M
Einnahmen:
$194.75M
Nettoeinkommen (Verlust:
$-51.26M
KGV:
-3.5769
EPS:
-0.52
Netto-Cashflow:
$-23.38M
1W Leistung:
+8.77%
1M Leistung:
+39.85%
6M Leistung:
+35.77%
1J Leistung:
+96.85%
1-Tages-Spanne:
Value
$1.78
$1.86
1-Wochen-Bereich:
Value
$1.63
$1.86
52-Wochen-Spanne:
Value
$0.80
$2.48

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name
Firmenname
Akebia Therapeutics Inc
Name
Telefon
617-871-2098
Name
Adresse
245 FIRST STREET, CAMBRIDGE, MA
Name
Mitarbeiter
167
Name
Twitter
@akebiatx
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
AKBA's Discussions on Twitter

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2022-03-31 Herabstufung H.C. Wainwright Buy → Neutral
2022-03-31 Herabstufung Mizuho Buy → Neutral
2022-03-31 Herabstufung Needham Buy → Hold
2022-03-31 Herabstufung Piper Sandler Overweight → Neutral
2021-03-08 Eingeleitet Cantor Fitzgerald Overweight
2021-01-29 Herabstufung JP Morgan Neutral → Underweight
2019-11-14 Bestätigt Needham Buy
2019-08-06 Bestätigt H.C. Wainwright Buy
2019-07-11 Bestätigt H.C. Wainwright Buy
2019-05-02 Eingeleitet JP Morgan Overweight
2019-03-20 Eingeleitet Citigroup Neutral
2018-09-07 Fortgesetzt Morgan Stanley Equal-Weight
2018-08-10 Bestätigt Needham Buy
2018-06-06 Bestätigt H.C. Wainwright Buy
2017-12-19 Eingeleitet Piper Jaffray Overweight
2017-12-07 Eingeleitet BTIG Research Buy
2017-09-15 Eingeleitet RBC Capital Mkts Sector Perform
2017-07-10 Bestätigt H.C. Wainwright Buy
2017-04-27 Bestätigt H.C. Wainwright Buy
2017-04-27 Bestätigt Needham Buy
2016-12-27 Bestätigt H.C. Wainwright Buy
2016-12-20 Bestätigt JMP Securities Mkt Outperform
2016-11-15 Eingeleitet Aegis Capital Buy
2016-09-29 Eingeleitet Brean Capital Buy
2016-03-16 Bestätigt Needham Buy
2016-01-21 Eingeleitet Credit Suisse Neutral
Alle ansehen

Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten

pulisher
06:59 AM

Here's Why You Should Consider Buying Akebia (AKBA) Stock - MSN

06:59 AM
pulisher
Nov 04, 2024

Akebia Therapeutics to present at upcoming investor conferences - MSN

Nov 04, 2024
pulisher
Nov 02, 2024

Akebia Therapeutics (AKBA) Set to Announce Earnings on Thursday - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Lelezard

Nov 01, 2024
pulisher
Nov 01, 2024

Akebia Therapeutics Signs Commercial Supply Contract with Leadin - GuruFocus.com

Nov 01, 2024
pulisher
Nov 01, 2024

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights - citybiz

Nov 01, 2024
pulisher
Oct 31, 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Down 6.0% in October - Defense World

Oct 31, 2024
pulisher
Oct 31, 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update - MarketBeat

Oct 31, 2024
pulisher
Oct 25, 2024

Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Reaffirmed by HC Wainwright - Defense World

Oct 25, 2024
pulisher
Oct 23, 2024

Akebia stock climbs 8% on dialysis provider supply agreement - MSN

Oct 23, 2024
pulisher
Oct 23, 2024

High Growth Tech Stocks to Watch in October 2024 - Simply Wall St

Oct 23, 2024
pulisher
Oct 23, 2024

Akebia Therapeutics (NASDAQ:AKBA) shareholder returns have been respectable, earning 91% in 1 year - Simply Wall St

Oct 23, 2024
pulisher
Oct 22, 2024

Akebia Therapeutics secures dialysis drug contract By Investing.com - Investing.com Australia

Oct 22, 2024
pulisher
Oct 22, 2024

Akebia Therapeutics secures dialysis drug contract - Investing.com

Oct 22, 2024
pulisher
Oct 22, 2024

Akebia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow

Oct 22, 2024
pulisher
Oct 22, 2024

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis - Yahoo Finance

Oct 22, 2024
pulisher
Oct 17, 2024

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class ActionAKBA - AsiaOne

Oct 17, 2024
pulisher
Oct 16, 2024

Akebia Therapeutics extends supply agreement with STA Pharmaceutical - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Akebia Therapeutics extends supply agreement with STA Pharmaceutical By Investing.com - Investing.com UK

Oct 16, 2024
pulisher
Oct 16, 2024

Akebia Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow

Oct 16, 2024
pulisher
Oct 15, 2024

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024 - StockTitan

Oct 15, 2024
pulisher
Oct 14, 2024

A new trading data show Akebia Therapeutics Inc. (AKBA) is showing positive returns. - SETE News

Oct 14, 2024
pulisher
Oct 14, 2024

Akebia Therapeutics Inc.’s latest rating changes from various analysts - Knox Daily

Oct 14, 2024
pulisher
Oct 12, 2024

Akebia shares maintain Buy rating on CMS Vafseo payment decision By Investing.com - Investing.com Canada

Oct 12, 2024
pulisher
Oct 12, 2024

Marshall Wace LLP Lowers Stake in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - MarketBeat

Oct 12, 2024
pulisher
Oct 12, 2024

Akebia shares maintain Buy rating on CMS Vafseo payment decision - Investing.com India

Oct 12, 2024
pulisher
Oct 11, 2024

CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025 - Lelezard

Oct 11, 2024
pulisher
Oct 10, 2024

Akebia Therapeutics Inc. [AKBA] Records 200-Day SMA of $1.3806 - Knox Daily

Oct 10, 2024
pulisher
Oct 09, 2024

Akebia Therapeutics Inc (AKBA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Revenue Challenges - GuruFocus.com

Oct 09, 2024
pulisher
Oct 09, 2024

Akebia Therapeutics Inc (AKBA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

A stock that deserves closer examination: Akebia Therapeutics Inc. (AKBA) - US Post News

Oct 09, 2024
pulisher
Oct 08, 2024

Ratio Revelations: Akebia Therapeutics Inc. (AKBA)’s Financial Metrics in the Spotlight - The Dwinnex

Oct 08, 2024
pulisher
Oct 08, 2024

Akebia shares gain momentum as analyst highlights Vafseo's market potential in dialysis centers - Investing.com

Oct 08, 2024
pulisher
Oct 08, 2024

Akebia Therapeutics (NASDAQ:AKBA) Given "Buy" Rating at HC Wainwright - MarketBeat

Oct 08, 2024
pulisher
Oct 07, 2024

Examining the Potential Price Growth of Akebia Therapeutics Inc. (AKBA) - Knox Daily

Oct 07, 2024
pulisher
Oct 07, 2024

Akebia, U.S. Renal Care sign dialysis treatment supply deal - Investing.com

Oct 07, 2024
pulisher
Oct 07, 2024

Akebia, U.S. Renal Care sign dialysis treatment supply deal By Investing.com - Investing.com UK

Oct 07, 2024
pulisher
Oct 07, 2024

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis - Marketscreener.com

Oct 07, 2024
pulisher
Oct 07, 2024

Akebia Therapeutics Inc. (AKBA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News

Oct 07, 2024
pulisher
Oct 03, 2024

SVP, Chief Legal Officer Hadas Nicole R. sale 12,016 shares of Akebia Therapeutics Inc. [AKBA] - Knox Daily

Oct 03, 2024
pulisher
Oct 03, 2024

Akebia Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 13, 2022 to Discuss Your RightsAKBA - Newsfile

Oct 03, 2024
pulisher
Sep 26, 2024

Chartwell Partners Recruits CFO for Akebia Therapeutics - Hunt Scanlon Media

Sep 26, 2024
pulisher
Sep 25, 2024

Alerce Investment Management L.P. Sells 7,457,213 Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) - MarketBeat

Sep 25, 2024
pulisher
Sep 24, 2024

Ratios in Focus: Analyzing Akebia Therapeutics Inc. (AKBA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Sep 24, 2024

Finanzdaten der Akebia Therapeutics Inc-Aktie (AKBA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$12.67
price up icon 0.88%
$114.96
price down icon 0.42%
$89.24
price up icon 3.56%
$58.48
price down icon 0.36%
$121.53
price up icon 0.83%
$11.61
price up icon 1.40%
Kapitalisierung:     |  Volumen (24h):